Has Aubrey de Grey publicly confirmed taking specific longevity compounds by name?

De Grey has confirmed personal experimentation with longevity compounds in podcast interviews, including conversations with Lex Fridman and Peter Attia. He has not always disclosed a specific named compound list or dosing regimen on the public record. The HealthRX Medical Team has constructed the compound discussion from his SENS framework and his public statements about personal experimentation, not from a confirmed private prescription list.

Is any longevity compound covered by health insurance?

Metformin is covered by insurance for type 2 diabetes. None of the compounds discussed here are covered for aging or longevity indications, because the FDA does not recognize aging as an approvable indication. Rapamycin is covered for transplant rejection. Dasatinib is covered for CML. Neither coverage applies to healthy adults seeking longevity benefits.

What is the cheapest way to access a longevity stack similar to the SENS framework?

The lowest-cost entry point is generic metformin (with a willing prescriber), low-dose generic rapamycin, and a third-party-tested NR or NMN supplement. Combined drug cost through discount pharmacies can be under $100 per month. The real cost is physician access. A concierge longevity practice typically costs $2,000 to $10,000 annually, which is the dominant expense for most patients.

Are senolytics safe for healthy adults?

The honest answer is that we do not know yet. Human trials to date have been small, short, and focused on disease populations rather than healthy adults. Dasatinib carries real risks including myelosuppression, fluid retention, and cardiac effects, as outlined in its FDA prescribing information. Using an oncology drug off-label in a healthy person carries risk that may not be justified by current evidence. Patients should discuss this with a physician who is familiar with the senolytic literature.

What is the TAME trial and why does it matter?

The TAME (Targeting Aging with Metformin) trial is a multi-site, placebo-controlled RCT testing whether metformin delays the onset of age-related diseases in non-diabetic adults aged 65 to 79. It is significant because it is the first large human trial designed to treat aging itself as the primary outcome. Results are expected in the late 2020s. If positive, they would provide the first RCT-level evidence for a geroprotective compound in humans and might open the door to insurance coverage arguments.

What Aubrey de Grey's Longevity Protocol Would Cost Outside a Celebrity Context

By HealthRX Medical Team

Published Jul 15, 2024Updated Jul 15, 2024Last reviewed Jul 15, 2024

At a glance

Public confirmation status: Aubrey de Grey has confirmed personal experimentation with longevity compounds in podcast interviews, including appearances on the Lex Fridman Podcast and Peter Attia's Drive. Specific compound names and doses have not always been disclosed on record.
Drug family: Longevity (senolytics, mTOR inhibitors, NAD+ precursors, biguanides)
FDA approval for aging: None. All uses discussed here are off-label.
Insurance coverage: Essentially zero for aging indications. Metformin is an exception for diabetes.
Monthly cost range (self-pay): $200 to $2,000+
Clinical evidence level: Varies from rodent models to small human pilot trials. No large RCT has validated longevity outcomes in humans for any of these compounds.

Who Is Aubrey de Grey and Why Does His Protocol Matter to Ordinary Patients?

Aubrey de Grey is a British-American biogerontologist who spent years at the University of Cambridge before co-founding the SENS Research Foundation, an organization focused on developing therapies to repair the molecular and cellular damage he argues underlies biological aging. His framework, Strategies for Engineered Negligible Senescence, categorizes aging damage into seven classes, including intracellular junk, extracellular junk, cell loss, and crucially for this discussion, the accumulation of senescent cells.

De Grey has been a guest on high-profile science podcasts including the Lex Fridman Podcast and the Peter Attia Drive, where he has confirmed that he personally takes compounds associated with the longevity research he advocates. He has not always specified exact doses or a complete compound list on the public record. The HealthRX Medical Team has therefore drawn the public record narrowly: we describe only what de Grey has confirmed or what falls clearly within the SENS intellectual framework he publicly champions. Anything beyond that is noted as speculated or unconfirmed.

The reason this matters to a non-celebrity patient is simple. De Grey is arguably the most prominent popularizer of the idea that aging is a disease amenable to medical intervention. Patients who follow his work often ask their physicians for these compounds. Physicians are then caught between patient demand, a thin but growing evidence base, no insurer support, and real safety questions. This page exists to give those patients a clear-eyed cost and access picture.

The Core Compound Classes: Mechanisms and Evidence

Senolytics: Dasatinib and Quercetin

Senescent cells are cells that have exited the cell cycle but resist apoptosis, secreting a pro-inflammatory cocktail called the senescence-associated secretory phenotype (SASP). The accumulation of these cells is strongly linked to age-related tissue dysfunction in animal models. The senolytic hypothesis holds that selectively clearing senescent cells should delay or reverse aspects of aging.

Dasatinib is an FDA-approved BCR-ABL tyrosine kinase inhibitor used in chronic myeloid leukemia. Quercetin is a plant-derived flavonoid available over the counter. The combination (D+Q) was identified as senolytic in a landmark 2015 paper by Zhu et al. in Aging Cell, which showed the pair reduced senescent cell burden in mice. The first human pilot trial, a small open-label study in patients with idiopathic pulmonary fibrosis published in EBioMedicine in 2019, showed functional improvements but involved only 14 participants. Larger human RCTs remain ongoing.

Cost reality: Dasatinib is a branded oncology drug. A 30-day supply of Sprycel (100 mg) lists at over $15,000 retail. Generic dasatinib became available in the United States after 2022 and can be sourced through GoodRx or Mark Cuban's Cost Plus Drugs for approximately $180 to $400 for a short-course senolytic protocol (typically two to five consecutive days per month rather than daily dosing, per the research protocols). Quercetin 500 mg capsules run $15 to $30 for a monthly supply. Insurance will not cover dasatinib for an aging indication. A prior authorization tied to a CML diagnosis is not an option for a healthy adult seeking off-label use.

Rapamycin (Sirolimus)

Rapamycin inhibits the mechanistic target of rapamycin complex 1 (mTORC1), a nutrient-sensing kinase that regulates cell growth, autophagy, and protein synthesis. Inhibiting mTOR in multiple organisms, from yeast to mice, extends lifespan. The Harrison et al. 2009 study in Nature demonstrated lifespan extension in mice even when rapamycin was started late in life, a finding that generated significant excitement in the field.

De Grey has publicly discussed rapamycin in the context of the SENS approach, and the compound is widely used in the longevity-medicine physician community. Doses used off-label for aging prevention are typically intermittent and low, often 5 to 10 mg once weekly, versus the daily immunosuppressive doses used in transplant medicine. No large human RCT has confirmed longevity outcomes at these doses.

Cost reality: Rapamycin (sirolimus) is available as a generic. Through Cost Plus Drugs, 30 tablets of 1 mg sirolimus cost approximately $35. At a common 6 mg weekly regimen, monthly cost is roughly $25 to $50 through discount channels. Compounding pharmacies offer rapamycin capsules or topical preparations at variable prices, $60 to $200 per month. Insurance covers sirolimus for transplant indications only. Off-label aging use is self-pay.

NAD+ Precursors: NMN and NR

Nicotinamide adenine dinucleotide (NAD+) levels decline with age in multiple tissues. NAD+ is essential for mitochondrial function and sirtuins, a family of deacylases implicated in metabolic regulation and DNA repair. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are orally bioavailable precursors that raise NAD+ levels in humans, as confirmed in Martens et al. 2020 in Cell Metabolism for NMN and in Trammell et al. 2016 in Nature Communications for NR. Whether raising NAD+ translates to meaningful longevity or health outcomes in humans remains under active investigation.

Cost reality: NMN and NR are sold as dietary supplements and are not regulated as drugs. Quality varies significantly between manufacturers. A reputable 500 mg/day NMN supplement from companies that publish third-party testing runs $60 to $120 per month. NR is similarly priced. Neither is covered by insurance. The FDA has raised regulatory questions about NMN's supplement status, which has created some market uncertainty.

Metformin

Metformin is a biguanide hypoglycemic agent approved for type 2 diabetes. Epidemiological data and animal studies have suggested potential geroprotective effects, likely through AMPK activation and mTOR suppression. The TAME (Targeting Aging with Metformin) trial, a large multi-site human RCT, is currently underway to formally test this hypothesis in non-diabetic adults.

Cost reality: Generic metformin is extraordinarily cheap. A 90-day supply of metformin 500 mg twice daily costs $4 to $15 at most major pharmacies. The barrier is not cost. The barrier is that prescribing metformin to a non-diabetic patient for longevity is off-label, and most primary care physicians are unwilling to do so without specialist consultation. Longevity-focused concierge physicians typically charge $2,000 to $10,000 per year for membership, which is where most patients accessing metformin off-label for aging actually obtain their prescriptions.

The HealthRX Medical Team Take

The HealthRX Medical Team wants to be direct about what the evidence does and does not support. De Grey's public advocacy has done real work in moving aging research toward mainstream scientific legitimacy. The SENS framework identified senescent cell clearance as a therapeutic target years before the first human senolytic trial. That is genuinely significant.

What the evidence does not yet support is a confident clinical recommendation for any of these compounds in healthy adults seeking longevity benefits. The FDA does not recognize aging as an indication, which means no compound can be approved for it, which means every use discussed here is off-label, which means no insurer will pay, which means access is gated by income.

A patient who reads de Grey's interviews and wants to replicate his protocol will face the following practical realities. First, they need a physician willing to prescribe off-label, which often means paying for a longevity-focused concierge practice, a cost not itemized in any supplement budget. Second, the most evidence-backed intervention in this stack, the D+Q senolytic combination, requires obtaining an oncology drug through a discount pharmacy. Third, the total monthly outlay for a complete stack, metformin, rapamycin, NMN, and intermittent D+Q, runs $150 to $350 per month in drug costs alone, plus physician fees.

That is not nothing. It is also not $2,000, which is what early press coverage of "longevity medicine" sometimes implied. The actual cost barrier is more about physician access than pharmacy cost, and that is a structural problem the supplement and longevity-medicine industries have not solved.

Frequently asked questions

›

References

Zhu Y, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015. https://pubmed.ncbi.nlm.nih.gov/26139916/
Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019. https://pubmed.ncbi.nlm.nih.gov/30975895/
Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009. https://pubmed.ncbi.nlm.nih.gov/19587680/
Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Cell Metabolism. 2018. https://pubmed.ncbi.nlm.nih.gov/29514072/ (see also Yoshino M, et al. 2021 for NMN: https://pubmed.ncbi.nlm.nih.gov/32877690/)
Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nature Communications. 2016. https://pubmed.ncbi.nlm.nih.gov/27721479/
Barzilai N, et al. Metformin as a tool to target aging. Cell Metabolism. 2016. https://pubmed.ncbi.nlm.nih.gov/34416415/
FDA prescribing information for dasatinib (Sprycel). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021986s019lbl.pdf
FDA New Dietary Ingredient notification process and NMN status. https://www.fda.gov/food/new-dietary-ingredients-ndi-notification-process/new-dietary-ingredient-ndi-notification-list
Lex Fridman Podcast, Aubrey de Grey appearance. https://www.youtube.com/watch?v=4GEBx8-mBjc
Peter Attia Drive Podcast, Aubrey de Grey appearance. https://peterattiamd.com/aubrey-de-grey/